Sharemaestro company-news research for Eli Lilly and Company (LLY), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NYSE
United States
Measured evidence
Company news sentiment
LLY news sentiment
Eli Lilly and Company
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score55Neutral is 50
Balanced news tone
50/100 evidence confidence
96% direct company focus
38 current stories across 16 publishers
Current company news
Balanced news tone
The score uses 38 current company stories from 16 publishers.
Observed headline tone57/100
→
Published 30-day score55/100
Latest source headline
Eli Lilly Stock Falls While Retatrutide Lawsuits Expand
finance.yahoo.com · 12 Aug 2026 17:24
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
38 current stories are mapped specifically to LLY.
The score uses 16 publishers rather than depending on one outlet.
The current stories agree at 84/100.
What limits the score
No major limit stands out.
55/100
News scoreBalanced news tone
50/100
Confidencebuilding confidence
96%/100
Company news38 company stories
84/100
Story agreement16/100 difference
News history
Daily score and story count over 30 days
15 Jul30 Jul13 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence37
1.849 after freshness weightingSource breadth100
16 independent publishersCompany relevance96
share tied directly to this companyFreshness58
recency-weighted evidenceAgreement84
how closely stories agreePublisher mix39
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
News tone and price action are not far from neutral.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202647USD 1185.71+3.2%
31 Jul 202652USD 1148.84-3.9%
24 Jul 202650USD 1196.03+1.4%
17 Jul 202650USD 1179.11-0.8%
10 Jul 202651USD 1188.58-2.1%
03 Jul 202650USD 1213.91+0.5%
26 Jun 202650USD 1208.12+10.0%
News subjects
What is shaping the score
Market update4717 stories · 45%
Regulatory and legal4911 stories · 29%
Earnings758 stories · 21%
Analyst action501 stories · 3%
Deals and strategy501 stories · 3%
Source mix
Where the evidence comes from
finance.yahoo.com5718 stories · 47%
Motley Fool503 stories · 8%
nasdaq.com632 stories · 5%
Simply Wall St.502 stories · 5%
GuruFocus.com502 stories · 5%
Zacks661 stories · 3%
seekingalpha.com501 stories · 3%
Recurring subjects
Subjects appearing most often
Earnings7EARNINGS7Pharma6PHARMA6Clinical Trials6CLINICAL-TRIALS6Fda Approval5FDA-APPROVAL5Obesity4OBESITY4
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
20 Jun50 neutral13 Aug 22:39
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Aug 22:39 | 59 | +0 | 65/100 (+1) | 90 (+11) | Measured |
| 12 Aug 23:59 | 59 | -2 | 64/100 (+2) | 79 (+12) | Measured |
| 11 Aug 23:59 | 61 | +0 | 62/100 (+3) | 67 (+11) | Measured |
| 10 Aug 23:59 | 61 | +2 | 59/100 (+8) | 56 (+16) | Measured |
| 09 Aug 23:59 | 59 | +1 | 51/100 (-1) | 40 (+1) | Measured |
| 08 Aug 23:59 | 58 | +11 | 52/100 (+17) | 39 (+10) | Measured |
| 07 Aug 23:59 | 47 | -4 | 35/100 (+5) | 29 (0) | Provisional |
| 05 Aug 23:59 | 51 | +0 | 30/100 (-1) | 29 (-2) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#140Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly Stock Falls While Retatrutide Lawsuits Expand
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for human use, sometimes hiding behind research use only labels. Lilly shares slipped roughly 0.8% Wednesday morning, but this fight is much bigger than one day's stock move. Lilly is defending a drug
CLINICAL-TRIALSClinical TrialsLAWSUITSLawsuitsOBESITYObesity
- Published
- 12 Aug 2026 17:24
- News subject
- Regulatory and legal
- Why this score
- Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 8.1% · 1.1d old
- Duplicates
- 767 consolidated
#237Tone
finance.yahoo.comDirect company coverageStored article
Lilly Targets Black-Market Retatrutide Sellers
This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development. Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditi
CLINICAL-TRIALSClinical TrialsLAWSUITSLawsuitsPHARMAPharma
- Published
- 12 Aug 2026 16:54
- News subject
- Regulatory and legal
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 7.8% · 1.1d old
- Duplicates
- 767 consolidated
#350Tone
seekingalpha.comDirect company coverageStored article
Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots
[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide remains an investigational Phase 3 molecule, and no retatrutide medicine has been approved for human use by any regulator worldwide. The FDA has made c
FDAFdaPHARMAPharmaREGULATIONRegulation
- Published
- 12 Aug 2026 09:41
- News subject
- Regulatory and legal
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.2% · 1.4d old
- Duplicates
- 1535 consolidated
#450Tone
finance.yahoo.comDirect company coverageStored article
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors an
CLINICAL-TRIALSClinical TrialsFDA-APPROVALFda ApprovalHEALTHCAREHealthcare
- Published
- 12 Aug 2026 09:30
- News subject
- Regulatory and legal
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 4.7% · 1.5d old
- Duplicates
- 767 consolidated
#555Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly Scores Major Win in Weight-Loss Drug Race
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator.
FDA-APPROVALFda ApprovalOBESITYObesityPHARMAPharma
- Published
- 11 Aug 2026 19:07
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 6.7% · 2.1d old
- Duplicates
- 767 consolidated
#650Tone
finance.yahoo.comDirect company coverageStored article
Lilly Takes Its Weight-Loss Pill Battle Overseas
This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo
FDA-APPROVALFda ApprovalHEALTHCAREHealthcarePHARMAPharma
- Published
- 11 Aug 2026 15:12
- News subject
- Regulatory and legal
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.8% · 2.2d old
- Duplicates
- 767 consolidated
#735Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?
The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial
CLINICAL-TRIALSClinical TrialsFINANCIAL RESULTSFinancial ResultsLAWSUITLawsuit
- Published
- 11 Aug 2026 12:44
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.7% · 2.3d old
- Duplicates
- 1535 consolidated
#850Tone
finance.yahoo.comDirect company coverageStored article
Veeva Vault CRM Selected by Eli Lilly and Company
PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of applications that provides the technology foundation for agentic commercial, the new commercial model that leverages AI to get the right medicines to more patients. "We are excited to expand our strategic work with Veeva by moving to Vault CRM," said Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly.
BIOTECHBiotechCRMCrmPHARMAPharma
- Published
- 11 Aug 2026 11:03
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.9% · 2.4d old
- Duplicates
- 1535 consolidated
#967Tone
nasdaq.comDirect company coverageStored article
Eli Lilly's Foundayo Wins UK Approval
(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory Agency (MHRA) on August 10, 2026, follows the U.S. FDA's approval in April 2026, positioning Foundayo as a key entrant in the competitive obesity and diabetes market. Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist designed for convenient daily use without food or water restrictions. Clinical data
BIOTECHBiotechDIABETESDiabetesEARNINGSEarnings
- Published
- 11 Aug 2026 07:30
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 9.9% · 2.5d old
- Duplicates
- 1535 consolidated
#1050Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly's updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay
DIABETESDiabetesEARNINGSEarningsOBESITYObesity
- Published
- 10 Aug 2026 23:20
- News subject
- Analyst action
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2% · 2.9d old
- Duplicates
- 767 consolidated
#1142Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?
For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of a competitive advantage than an operational consideration. That shift creates a new question for investors. If domestic manufacturing becomes a larger determinant of pricing, regulatory flexibility, and suppl
FDAFdaMANUFACTURINGManufacturingOBESITY-DRUGSObesity Drugs
- Published
- 10 Aug 2026 22:21
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.4% · 2.9d old
- Duplicates
- 767 consolidated
#1250Tone
nasdaq.comDirect company coverageStored article
Why Eli Lilly Topped the Market Today
Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly › Eli Lilly(NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided plenty of optimism for these types of drugs, which have been hotly popular for years now. The popular pill The product in question is Lilly's Foundayo, its first weight
EUROPEEuropeMARKETSMarketsOBESITY-TREATMENTSObesity Treatments
- Published
- 10 Aug 2026 22:13
- News subject
- Regulatory and legal
- Why this score
- No clear positive or negative phrase
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.2% · 2.9d old
- Duplicates
- 1535 consolidated
#1350Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?
The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare's fastest-growing markets. Yet another competitive advantage for investors to keep in mind is manufacturing. During the early stages of the GLP-1 boom, demand consistently exceeded supply. Shortages of Wegovy, Ozempic, Mounjaro, and Zepbound demonstrated that developing a breakthro
MANUFACTURINGManufacturingOBESITY-MARKETObesity MarketPHARMAPharma
- Published
- 10 Aug 2026 21:39
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1% · 2.9d old
- Duplicates
- 767 consolidated
#1450Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and type 2 diabetes. Lilly shares rose approximately 2.1% in regular trading. The appeal is easy to understand: no injection. Foundayo targets GLP-1 while giving patients an oral alternative to Lilly's blockbuster Mounjaro and Zepbound. The pill entered the U.S. market in April and generated $98 m
FDA-APPROVALFda ApprovalGLP-1Glp 1OBESITYObesity
- Published
- 10 Aug 2026 19:35
- News subject
- Regulatory and legal
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.5% · 3.0d old
- Duplicates
- 767 consolidated
#1550Tone
finance.yahoo.comDirect company coverageStored article
Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs
Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading
- Published
- 10 Aug 2026 05:00
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.8% · 3.6d old
- Duplicates
- 767 consolidated
#1682Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook
Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and profit targets. Shares moved higher the same day as investors focused on how fast the obesity franchise is still expanding.Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook Bull Case: Weight Loss Demand Still Has Room To Run The headline number came from Mounjaro and Zepbound. Mounjaro revenue jumped 91% to $9.9 billion, while Zepbou
EARNINGSEarningsGUIDANCEGuidanceHEALTHCAREHealthcare
- Published
- 09 Aug 2026 08:51
- News subject
- Earnings
- Why this score
- Guidance raised, Improving financial comparison
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 8.2% · 4.5d old
- Duplicates
- 767 consolidated
#1775Tone
finance.yahoo.comDirect company coverageStored article
LLY Q2 Deep Dive: Key Products and Pipeline Expansion
Global pharmaceutical company Eli Lilly (NYSE:LLY)reported Q2 CY2026 results topping the market's revenue expectations , with sales up 47.7% year on year to $22.97 billion. The company's full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts' estimates. Its non-GAAP profit of $8.38 per share was 27.3% above analysts' consensus estimates. Is now the time to buy LLY? Find out in our full research report (it's free for active Edge members). Eli Lilly (LLY) Q2 CY2026 Highlights: Revenue: $22.97 billion vs analyst estimates of $20.62 billion (47.7% year-on-year growth
DIABETESDiabetesEARNINGSEarningsGUIDANCEGuidance
- Published
- 08 Aug 2026 21:25
- News subject
- Earnings
- Why this score
- Beat expectations
- Company focus
- Company discussed · 86%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.3% · 5.0d old
- Duplicates
- 768 consolidated
#1857Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly (LLY) Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with a KRAS G12C mutation. The company entered a new clinical trial collaboration with Amplia Therapeutics to test olomorasib in combination with Amplia's FAK inhibitor narmafotinib in advanced non small cell lung cancer. These developments highlight Eli Lilly's efforts to broaden its oncology portf
CLINICAL-TRIALSClinical TrialsFDA-APPROVALFda ApprovalHEALTHCAREHealthcare
- Published
- 08 Aug 2026 21:16
- News subject
- Regulatory and legal
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 4.6% · 5.0d old
- Duplicates
- 1535 consolidated
#1957Tone
finance.yahoo.comDirect company coverageStored article
BofA points to the Eli Lilly market that could outsize the U.S.
Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped driving the conversation. Bank of America came out of the earnings call pointing to a different number. The bank thinks the obesity market outside the United States could eventually surpass U.S. sales of the same drugs. For anyone holding LLY or considering it, that international call is worth a closer look. Why Bank of America raised its Eli Lill
DRUG-DEVELOPMENTDrug DevelopmentEARNINGSEARNINGS ESTIMATEEarningsEarnings Estimate
- Published
- 08 Aug 2026 18:33
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2.1% · 5.1d old
- Duplicates
- 1535 consolidated
#2085Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly and Company Q2 Earnings Call Highlights
Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Lilly reported 48% year-over-year revenue growth in Q2 2026, with MOUNJARO and ZEPBOUND generating $14.9 billion in combined sales. The company raised its full-year revenue outlook to $85 billion–$87 billion and adjusted earnings-per-share guidance to $35.50–$36.50. Demand for obesity medicines remained strong, with U.S. obesity prescriptions up 78% year over year. Lilly said the Medicare GLP-1 Bridge Program expanded coverage for its obesity medicines by 35%, while Foundayo's launch continued gaining prescrib
BUSINESS-DEVELOPMENTBusiness DevelopmentEARNINGSEARNINGS PER SHAREEarningsEarnings Per Share
- Published
- 08 Aug 2026 16:04
- News subject
- Earnings
- Why this score
- Guidance raised, Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 8.9% · 5.2d old
- Duplicates
- 1535 consolidated
#2150Tone
finance.yahoo.comDirect company coverageStored article
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem
Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from the U.S. Food and Drug Administration for retatrutide in the first quarter of 2027. This new product could help Eli Lilly extend its lead over its biggest competitor in this space, Novo Nordisk (NYSE: NVO). Here's the rundown. Best-in-class efficacy In a phase 3 study, retatrutide posted an average
CLINICAL-TRIALSClinical TrialsEARNINGSEARNINGS PER SHAREEarningsEarnings Per Share
- Published
- 07 Aug 2026 22:50
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.5% · 5.9d old
- Duplicates
- 1535 consolidated
#2250Tone
BenzingaDirect company coverageScored from headlineSource lookup
Why Is Eli Lilly Stock Gaining Wednesday? - Eli Lilly (NYSE:LLY)
- Published
- 05 Aug 2026 16:27
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.2% · 8.2d old
- Duplicates
- 10 consolidated
#2350Tone
FinancialContentDirect company coverageScored from headlineSource lookup
What To Expect From Eli Lilly’s (LLY) Q2 Earnings
- Published
- 04 Aug 2026 05:00
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.2% · 9.6d old
- Duplicates
- 10 consolidated
#2450Tone
Simply Wall St.Direct company coverageScored from headlineSource lookup
Eli Lilly (LLY) Wins FDA Breakthrough Tag For Olomorasib, Backs $70 Million Raise
- Published
- 03 Aug 2026 22:30
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 9.9d old
- Duplicates
- 10 consolidated
#2550Tone
Stocks Down UnderDirect company coverageScored from headlineSource lookup
Eli Lilly’s (NYSE:LLY) Weight-Loss Drugs Could Bring In $13 Billion This Quarter- but Is It Enough?
- Published
- 02 Aug 2026 18:37
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1% · 11.1d old
- Duplicates
- 10 consolidated
#2650Tone
Motley FoolDirect company coverageScored from headlineSource lookup
Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.
- Published
- 31 Jul 2026 19:27
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 13.0d old
- Duplicates
- 10 consolidated
#2750Tone
Hospital ManagementDirect company coverageScored from headlineSource lookup
Resilience and Lilly to increase US medicines production with $750m investment
- Published
- 31 Jul 2026 10:43
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 13.4d old
- Duplicates
- 10 consolidated
#2850Tone
GuruFocus.comDirect company coverageScored from headlineSource lookup
Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
- Published
- 30 Jul 2026 17:57
- News subject
- Deals and strategy
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1% · 14.1d old
- Duplicates
- 10 consolidated
#2950Tone
Simply Wall St.Direct company coverageScored from headlineSource lookup
Eli Lilly (LLY) Joins Illumina’s Billion Cell Atlas For AI Drug Discovery
- Published
- 30 Jul 2026 14:30
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 14.2d old
- Duplicates
- 10 consolidated
#3066Tone
ZacksDirect company coverageScored from headlineSource lookup
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
- Published
- 29 Jul 2026 17:47
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.3% · 15.1d old
- Duplicates
- 10 consolidated
Earlier company news
LLY news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 25 older LLY headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to LLY, but the headline and available text are not mainly about Eli Lilly and Company. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Aug132026
finance.yahoo.comProvider mentionNot included in score
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment
- Published
- 13 Aug 2026 19:38
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
West Pharmaceutical Services, Inc. WST is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share. The question is whether those gains justify a valuation well above industry levels. WST's growth drivers remain attractive, but the premium multiple leaves less room for operational missteps. WST's HVP Growth Supports the Bull Case HVP Components generated $424.1 million in second-quarter sales, or 49% of total company revenues, and grew 18.4% organic
- Published
- 13 Aug 2026 18:48
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
West Pharmaceutical Services, Inc. WST turned a better-than-expected second quarter into a higher 2026 outlook. Organic sales growth accelerated, margins widened and adjusted earnings increased sharply, giving investors a clearer read on how High-Value Product demand is translating into financial performance. The quarter matters because the guidance increase was supported by broad HVP momentum rather than a single product line. Execution risks remain in West Vantage and the SmartDose transition, but the earnings trajectory improved. WST's Q2 Beat Resets 2026 Expectations Adjusted earnings rose
- Published
- 13 Aug 2026 18:48
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
Novo Nordisk Escalates Weight-Loss War With Eli Lilly
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead in the U.S. obesity-drug market, raising the stakes for Novo as it tries to narrow the efficacy gap consumers may perceive between Wegovy and Zepbound. Is LLY fairly valued? Test your thesis with our free DCF calculator. Novo Nordisk develops treatments for diabetes, obesity and other chronic disea
- Published
- 13 Aug 2026 18:32
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?
Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely driven by the performance of the Wegovy pill, the first oral GLP-1 approved for weight loss, which Novo Nordisk launched in the U.S. in January. The Wegovy pill beat expectations in the first quarter but came up short in the second. What does this mean for the company's prospects?Image source: The Motley
- Published
- 13 Aug 2026 18:20
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
European Stocks Close Mixed in Thursday Trading; UK GDP Growth Slows in Q2
The European stock markets closed mixed in Thursday trading as The Stoxx Europe edged 0.1% lower, Ge PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
- Published
- 13 Aug 2026 16:54
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk an
- Published
- 13 Aug 2026 16:12
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings To Improve Access, Affordability, Care and Support for GLP-1 Medications
WOONSOCKET, RI / ACCESS Newswire / August 13, 2026 / Originally published on CVS Health Company Newsroom CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options. New collaboration with Eli Lilly and Company will provide eligible Zepbound and Foundayo patients an additional access point at CVS Pharmacy through the CVS Health app MinuteClinic digital weight loss visits lowered to $29, the most affordable option in the market, available 24/7 Combines an online visit with a licensed clinician, same-day medication pickup at 9,000 local CVS Pharmacy locations, and
- Published
- 13 Aug 2026 15:30
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite NVO delivering a better-than-expected second-quarter 2026 performance. NVO's reported second-quarter sales rose 3% to $12.21 billion (DKK 78.5 billion) at constant exchange rates (CER). More importantly, its key GLP-1 brands showed signs of slowing. Ozempic generated $4.88 billion (DKK 31.4 billion) in repo
- Published
- 13 Aug 2026 15:26
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
2 S&P 500 Stocks with Exciting Potential and 1 We Ignore
2 S&P 500 Stocks with Exciting Potential and 1 We Ignore The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition. Picking the right S&P 500 stocks requires more than just buying big names, and that's where StockStory comes in. That said, here are two S&P 500 stocks that could deliver good returns and one that may struggle. One Stock to Sell: Hartford (HIG) Market Cap: $38.23
- Published
- 13 Aug 2026 15:05
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
Eli Lilly and Company LLY announced second-quarter results on Aug. 5. Investors were keen to know the first sales numbers and initial launch uptake of Lilly's new once-daily oral GLP-1 pill, Foundayo (orforglipron) for treating obesity, which was launched in April. Foundayo (orforglipron) generated $98 million in sales in the second quarter, its first full quarter on the market. Lilly expects Foundayo to be a commercial game-changer for the company as oral pills are expected to be a more convenient alternative to the currently available once-weekly injectable obesity treatments like Lilly's Ze
- Published
- 13 Aug 2026 14:42
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
OPKO Health, Inc. Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO's royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature i
- Published
- 13 Aug 2026 14:15
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug132026
finance.yahoo.comProvider mentionNot included in score
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?
Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets over $812.25 million, making it one of the average sized ETFs attempting to match the Large Cap Value segment of the US equity market. Why Large Cap Value Large cap companies usually have a market capitalization above $10 billion. Considered a more stable option, large cap companies boast more predictable cash flows and are less volat
- Published
- 13 Aug 2026 11:20
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug122026
finance.yahoo.comProvider mentionNot included in score
Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales
- Published
- 12 Aug 2026 18:29
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug122026
finance.yahoo.comProvider mentionNot included in score
Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci's recent early Phase 1 ABS-201 update and Eli Lilly's US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareh
- Published
- 12 Aug 2026 18:11
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug122026
finance.yahoo.comProvider mentionNot included in score
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo
- Published
- 12 Aug 2026 16:10
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug122026
finance.yahoo.comProvider mentionNot included in score
Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?
Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20
- Published
- 12 Aug 2026 16:03
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug122026
nasdaq.comProvider mentionNot included in score
1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run
Key Points The "Magnificent Seven" stocks account for over 53% of this Vanguard ETF. This has helped the ETF outperform the S&P 500 in 13 of the past 20 years. Sluggish performance among its top 10 holdings has slowed returns this year.10 stocks we like better than Vanguard Morningstar Growth ETF › The S&P 500 is the stock market's most important index, tracking the 500 largest American companies on the market. It has become the main benchmark investors use to measure their returns, with outperformance and underperformance largely dependent on how it compares. Although investing in an S&P 500
- Published
- 12 Aug 2026 15:35
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug122026
finance.yahoo.comProvider mentionNot included in score
IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point
Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens. Continue Reading
- Published
- 12 Aug 2026 15:29
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
Aug122026
finance.yahoo.comProvider mentionNot included in score
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001
IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro
- Published
- 12 Aug 2026 12:30
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.